WO2011054185A1 - Optical isomers of aralkyl piperazine derivative, preparation methods and uses thereof - Google Patents

Optical isomers of aralkyl piperazine derivative, preparation methods and uses thereof Download PDF

Info

Publication number
WO2011054185A1
WO2011054185A1 PCT/CN2010/001766 CN2010001766W WO2011054185A1 WO 2011054185 A1 WO2011054185 A1 WO 2011054185A1 CN 2010001766 W CN2010001766 W CN 2010001766W WO 2011054185 A1 WO2011054185 A1 WO 2011054185A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
camphorsulfonate
optical isomer
preparation
Prior art date
Application number
PCT/CN2010/001766
Other languages
French (fr)
Chinese (zh)
Inventor
王丙林
刘长鹰
杨汉煜
马玉秀
于普
郭文敏
郭小丰
宋灵杰
Original Assignee
石药集团中奇制药技术(石家庄)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 石药集团中奇制药技术(石家庄)有限公司 filed Critical 石药集团中奇制药技术(石家庄)有限公司
Publication of WO2011054185A1 publication Critical patent/WO2011054185A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Definitions

  • the present invention relates to optical isomers of N 1 -benzyl-N 4 -[l-(5,-chloro-6'-methoxy-2'-naphthoyl)pentyl]piperazine (Compound B) and a preparation method thereof, and using the optical isomer of the above compound B to prepare a 1-butyl-2-hydroxyarkanol piperazine derivative N 1 -benzyl-N 4 -[l-butyl-2-(5, A method of optical isomers of -chloro-6'-methoxy-2,-naphthyl)hydroxyethyl]piperazine (Compound A). Background technique
  • the applicant first disclosed the 1-butyl-2-hydroxyarkanol piperazine derivative N 1 -benzyl-N 4 -[l-butyl-2-(5'-chloro-) in Chinese patent application CN101712658A. 6'-Methoxy-2,-naphthyl)hydroxyethyl]piperazine (formula of formula A below, sometimes referred to hereinafter as compound of formula A) and optical isomers thereof, and discloses a compound of formula A Its optical isomers have strong antidepressant activity as selective triple reuptake inhibitors of serotonin (5-HT), norepinephrine (NA) and dopamine (DA).
  • 5-HT serotonin
  • NA norepinephrine
  • DA dopamine
  • Race or Compound Formula A Compound Racemic Reaction Scheme 1
  • the compound of formula A contains two chiral carbon atoms having (1S, 2S:), (1R, 2R), (1S, 2R) and (1R, 2S) Four optical isomers, therefore, only the threo or erythrocyclic compound of formula A can be obtained by the above preparation method.
  • Reaction Scheme 2 The reaction raw materials of the method are easily obtained, and the obtained product does not need to be chemically resolved, and the optical purity is high.
  • this method also has the following disadvantages: 1) long synthetic route, complicated process; 2) harsh reaction conditions, requiring no water operation; 3) high toxicity of the intermediate, such as compound 8 has cytotoxicity; 4) low total yield , less than 1%; 5) high product cost, the cost per kilogram of product reached about 150,000 yuan. Therefore, there is an urgent need for a process for producing an optical isomer of a compound of the formula A at low cost, in a simple, high yield, and high purity, thereby realizing industrial production of an optical isomer of the formula A compound. Summary of the invention
  • an object of the present invention to provide an intermediate which can produce an optical isomer of the compound of the formula A, which is an optical isomer of the compound of the formula B, which is inexpensive, simple, and high in yield and high purity.
  • Another object of the present invention is to provide a process for the preparation of the above intermediates.
  • a further object of the present invention is to provide a process for producing an optical isomer of a compound of the formula A inexpensively, simply, and with high yield and high purity using the above intermediate.
  • the inventors of the present application conducted intensive studies and found that chirality is employed when using an optical isomer mixture or a racemate of a compound of formula B as a raw material.
  • the camphorsulfonic acid is used as a resolving agent to obtain an optical isomer of a compound of the formula B having high optical purity, thereby completing the present invention.
  • the present invention provides a process for producing an optical isomer of the compound of the above formula B, characterized in that the optical isomer of the compound of the formula B is used by using chiral camphorsulfonic acid as a resolving agent.
  • the mixture or racemate is chemically resolved.
  • the preparation method comprises the following steps (1) and (2):
  • the present invention also provides a process for producing an optical isomer of the compound represented by the above Structural Formula A, which comprises using the compound of the formula B in the S or R configuration obtained by the above production method as The raw material was subjected to a reaction as shown in the following Reaction Scheme 3.
  • the optical isomer of the compound of the formula B can be obtained simply and with high purity, and the optical isomer can be used in an inexpensive, simple, high-yield, high-purity manner.
  • An optical isomer of a compound of formula A having an antidepressant effect is prepared.
  • the optical isomer mixture or the racemic compound of the compound of the formula B is chemically resolved by using chiral camphorsulfonic acid as a resolving agent.
  • the preparation method comprises the following steps (1) and (2):
  • an optical isomer mixture or a racemate of the compound of the formula B is reacted with D- or L-camphorsulfonic acid in a solvent to form a diastereomeric salt S-form represented by the lower structural formula.
  • R-Form B Compound -L-camphorsulfonate
  • the compound of the formula B used in the above reaction can be produced by the method of CN101712658A.
  • an optical isomer mixture or a racemate of the D- or L-camphoric acid and the compound of the formula B may be used in any ratio.
  • the molar ratio of the optical isomer mixture or racemate of the D- or L-camphorsulfonic acid to the compound of the formula B is preferably from 10:1 to 0.5:1, more preferably from 5:1 to 1 from the viewpoint of cost. :1 , most preferably 2: 1.
  • the compound of the formula B has a certain solubility, and it is preferred that the compound of the formula B can be completely dissolved at room temperature or in a heated state.
  • the solubility of the optical isomer of the compound of formula B with the diastereomeric salt formed by D-camphorsulfonic acid or L-camphorsulfonic acid should be somewhat different.
  • the solvent is not particularly limited, and examples thereof include one or more selected from the group consisting of water, an alcohol, an ester, a ketone, a chlorinated hydrocarbon, an ether, a nitrile, an amide, and a sulfoxide.
  • acetone is more preferably selected from the group consisting of methanol, ethanol, isopropanol, aqueous alcohol solution, ethyl acetate, and the like in terms of yield and product purity.
  • acetone further preferably methanol, ethanol, 1:1 methanol-isopropyl Alcohol, aqueous alcohol solution.
  • the reaction temperature as the above reaction is not particularly limited and may be, for example, o ° c to the reflux temperature of the solvent.
  • the reaction time of the above reaction is not particularly limited, and may be, for example, 5 minutes to 72 hours, preferably 10 minutes to 24 hours.
  • a precipitate of the S-form B compound-D-camphorsulfonate or the R-form B compound-L-camphorsulfonate is formed, and the separation of the precipitate can be carried out by a method known in the art, for example, filtration. , centrifugation or decantation, etc., wherein the preferred method is filtration.
  • the obtained S-form B compound -D-camphorate or R-form B compound -L-camphorsulfonate precipitate can be further purified by a method such as recrystallization.
  • the solvent for recrystallization is not particularly limited, and one selected from the group consisting of methanol, ethanol, isopropanol, ethyl acetate, acetone, dichloromethane, chloroform, diethyl ether, methyl tert-butyl ether, and THF can be used.
  • One kind or two or more kinds, and one or two or more of methanol, ethanol, isopropyl alcohol, ethyl acetate and acetone are preferable from the viewpoints of yield and product purity.
  • the S-form B compound-D-camphorsulfonate or the R-form B compound-L-camphorsulfonate obtained in the above step (1) is alkalized in a water-insoluble organic solvent.
  • a corresponding S-form B compound or R-form B compound represented by the following formula is obtained.
  • the base may be selected from the group consisting of metal hydroxides, oxides, carbonates, hydrogencarbonates and amides, of which metal hydroxides and carbonates, such as hydroxides, are preferred.
  • metal hydroxides and carbonates such as hydroxides
  • Sodium, sodium carbonate the base may be used in an amount of 0.5 to 10 moles, preferably 1 to 5 moles, more preferably 2 to 4 moles per mole of the camphorsulfonate.
  • the reaction temperature of the above reaction is not particularly limited and may be, for example, from 0 ° C to the reflux temperature of the solvent.
  • the reaction time of the above reaction is not particularly limited and may be, for example, 5 minutes.
  • another optical isomer can be obtained after the chiral resolving agent is changed to its enantiomer.
  • the optical isomer of the compound of the formula (A) can be obtained by reducing the optical isomer of the obtained S-form B compound or the R-form B compound as shown in the following Reaction Scheme 3 to obtain (1S, 2R), (1S, 2S) Mixture or (1R, 2R), (1R, 2S) a mixture of optical isomers of the compound of formula A, and then separate the mixture of isomers to obtain (1S, 2R), (1S, 2S) optics of the compound of formula A, respectively Isomer or (1R, 2R), (1R, 2S) optical isomer.
  • the reduction reaction can be carried out, for example, by using NaBH 4 as a reducing agent in methanol, preferably at room temperature for 0.5 to 1 hour; or aluminum isopropoxide can be used as a reducing agent in isopropanol. It is preferably reacted at 60 to 65 ° C for 24 to 48 hours; or other reduction methods which are considered suitable by those skilled in the art.
  • the separation can be carried out, for example, using a silica gel column in which 200:1 of dichloromethane:methanol can be used as an eluent, or other separation methods deemed suitable by those skilled in the art can be employed.
  • the present invention provides a new route for the preparation of optical isomers of the compound of formula A by inexpensive, simple, high yield and high purity by successfully separating the optical isomer mixture or racemate of the compound of formula B. It has opened up a new path for industrial production.
  • the R, S-form B compound racemate (prepared by the method described in CN101712658A) 10g (0.0215mol) was added to 300ml of methanol, heated to dissolve, and added D-camphorsulfonic acid 10g (0.043 lmol) at 65° C reacted for 3 h. After the reaction, stir at 20 ° C
  • the R, S-form B compound racemate (prepared by the method described in CN101712658A) 20g (0.043mol) was added to 500ml of absolute ethanol, heated to dissolve, and added L-camphorsulfonic acid 20g (0.0862mol), The reaction was carried out at 68 ° C for 2.5 h. After the reaction, at 10 Stir at °C for 2 h. The crystal was precipitated and suction filtered to obtain 12 g of the compound of formula R---camphorsulfonate. The optical purity was 91.0% as determined by chiral liquid chromatography.
  • camphorsulfonate was recrystallized from acetone to obtain 9 g of an R-form B compound -L-camphorsulfonate having an optical purity of more than 99%.
  • Example 2 Referring to the preparation method of Example 1, the S-form B compound-D-camphorsulfonate was prepared under different reaction solvents, and recrystallized and purified. The results of the experiment are shown in Table 2 below: Table 2 Examples 3 ⁇ 11 experimental results
  • the S-form B compound camphorsulfonate 4.6 g was obtained by the preparation method of Example 1, and the optical purity was 99.3% as measured by chiral HPLC.
  • the optical isomer of the compound of the formula B of the present invention can be used to obtain an optical isomer of the compound of the formula B in a simple and high-purity manner, and the optical isomer can be used at a low cost, in a simple manner, and in a high yield.
  • the optical isomer of the compound of the formula A having an antidepressant effect is prepared in a high-purity manner.

Abstract

Preparation methods of optical isomers of compound of formula (B) and preparation methods of optical isomers of compound of formula (A) by using the said optical isomers of compound of formula (B) are disclosed, in which chiral camphor sulfonic acid acts as resolution reagent and the optical isomer mixtures or racemes of compound of formula (B) are chemically resoluted.. By using the optical isomers of the present compound of formula (B), the optical isomers of compound of formula (A) which are useful as antidepressants can be obtained with high yield and high purify.

Description

芳烷哌嗪衍生物光学异构体、 其制备方法及应用  Optical isomer of aralkyl piperazine derivative, preparation method and application thereof
技术领域 Technical field
本发明涉及 N1-苄基 -N4-[l-(5,-氯 -6'-甲氧基 -2'-萘甲酰基)戊基]哌 嗪(化合物 B ) 的光学异构体及其制备方法, 以及使用上述化合物 B 的光学异构体制备 1-丁基 -2-羟基芳烷醇哌嗪衍生物 N1-苄基 -N4-[l-丁 基 -2-(5,-氯 -6'-甲氧基 -2,-萘基)羟乙基]哌嗪(化合物 A ) 的光学异构体 的方法。 背景技术 The present invention relates to optical isomers of N 1 -benzyl-N 4 -[l-(5,-chloro-6'-methoxy-2'-naphthoyl)pentyl]piperazine (Compound B) and a preparation method thereof, and using the optical isomer of the above compound B to prepare a 1-butyl-2-hydroxyarkanol piperazine derivative N 1 -benzyl-N 4 -[l-butyl-2-(5, A method of optical isomers of -chloro-6'-methoxy-2,-naphthyl)hydroxyethyl]piperazine (Compound A). Background technique
申请人在中国专利申请 CN101712658A中首次批露了 1-丁基 -2-羟 基芳烷醇哌嗪衍生物 N1-苄基 -N4-[l-丁基 -2-(5'-氯 -6'-甲氧基 -2,-萘基) 羟乙基]哌嗪(其结构式如下式 A所示, 下文有时也称为式 A化合物) 及其光学异构体, 并且公开了式 A化合物及其光学异构体作为 5-羟色 胺 (5-HT ) 、 去甲腎上腺素 (NA ) 和多巴胺 (DA ) 选择性三重再摄 取抑制剂, 具有较强的抗抑郁活性。 The applicant first disclosed the 1-butyl-2-hydroxyarkanol piperazine derivative N 1 -benzyl-N 4 -[l-butyl-2-(5'-chloro-) in Chinese patent application CN101712658A. 6'-Methoxy-2,-naphthyl)hydroxyethyl]piperazine (formula of formula A below, sometimes referred to hereinafter as compound of formula A) and optical isomers thereof, and discloses a compound of formula A Its optical isomers have strong antidepressant activity as selective triple reuptake inhibitors of serotonin (5-HT), norepinephrine (NA) and dopamine (DA).
Figure imgf000003_0001
Figure imgf000003_0001
(A) 在上述专利申请中, 关于式 A化合物的制备, 公开了如下述反应 流程 1 所述, 通过 N1-苄基 -Ν4-[1-(5'-氯 -6,-甲氧基 -2,-萘甲酰基)戊基] 哌嗪(其结构式如式 Β所示, 下文有时也称为式 Β化合物) 来制备苏 式(Threo, 1SR, 2SR )或赤式(Erythro, 1SR, 2RS )式 A化合物消 旋体的方法。 (A) In the above patent application, with respect to the preparation of the compound of formula A, it is disclosed by N 1 -benzyl-Ν 4 -[1-(5'-chloro-6,-methoxy) as described in Reaction Scheme 1 below. Base-2,-naphthoyl)pentyl]piperazine (having a structural formula such as the formula ,, sometimes referred to hereinafter as a hydrazine compound) to prepare a threo (Threo, 1SR, 2SR) or a erythro (Erythro, 1SR) , 2RS) A method of formulating a compound racemate.
Figure imgf000004_0001
Figure imgf000004_0001
Figure imgf000004_0002
赤式或苏式的式 A化合物消旋体 反应流程 1 但是, 式 A化合物结构中含有两个手性碳原子, 具有(1S,2S:)、 (1R,2R)、 (1S,2R)和(1R,2S)四种光学异构体, 因此, 通过上述制备方法 仅能得到苏式或赤式的式 A化合物消旋体。 要想得到式 A化合物的单 一的光学异构体化合物, 还需要对苏式或赤式的式 A化合物消旋体进 一步进行拆分, 或者采用其它方法进行制备。
Figure imgf000004_0002
Race or Compound Formula A Compound Racemic Reaction Scheme 1 However, the compound of formula A contains two chiral carbon atoms having (1S, 2S:), (1R, 2R), (1S, 2R) and (1R, 2S) Four optical isomers, therefore, only the threo or erythrocyclic compound of formula A can be obtained by the above preparation method. In order to obtain a single optical isomer compound of the compound of formula A, it is also necessary to further resolve the racemic form of the compound of formula A in the threo or erythro form, or to prepare it by other methods.
为了合成式 A化合物的单一光学异构体, 在上述专利申请中还公 开了采用前手性化合物和柱层析分离的方法来合成上述光学异构体。 具体而言, 如下述反应流程 2所述, 以手性正亮氨酸 1为原料, 氨基 经邻苯二甲酰基保护, 羧基经草酰氯酰化, 生成化合物 3 , 再与化合物 4通过傅 -克反应生成化合物 5,化合物 5经异丙醇铝还原、水解得到化 合物 7, 化合物 7与化合物 8缩合得到化合物 9, 再经柱层析分离得到 光学纯的目标产物 (IX ) 。 In order to synthesize a single optical isomer of the compound of formula A, it is also disclosed in the above-mentioned patent application to synthesize the above optical isomers by a method using a prochiral compound and column chromatography. Specifically, as described in the following Reaction Scheme 2, the chiral isoleucine 1 is used as a raw material, the amino group is protected by an phthaloyl group, the carboxyl group is acylated with oxalyl chloride to form a compound 3, and the compound 4 is passed through a Fu- The gram reaction produces the compound 5, the compound 5 is reduced by aluminum isopropoxide, and hydrolyzed to obtain the compound 7, and the compound 7 is condensed with the compound 8 to obtain the compound 9, which is then subjected to column chromatography to obtain the objective product (IX) which is optically pure.
Figure imgf000005_0001
Figure imgf000005_0001
反应流程 2 该方法的反应原料容易获得, 所得产物不需进行化学拆分, 且光 学纯度高。 但是该方法也存在下述弊端: 1 )合成路线长, 工艺繁杂; 2 )反应条件苛刻, 需要无水操作; 3 ) 中间体毒性大, 如化合物 8 具 有细胞毒性; 4 )总收率比较低, 还不到 1%; 5 )产品成本高, 每公斤 产品成本达到约 15万元。 因此, 迫切需要一种能够廉价、 简便且高收 率、 高纯度地制备式 A化合物光学异构体的方法, 从而实现式 A化合 物光学异构体的工业化生产。 发明内容 Reaction Scheme 2 The reaction raw materials of the method are easily obtained, and the obtained product does not need to be chemically resolved, and the optical purity is high. However, this method also has the following disadvantages: 1) long synthetic route, complicated process; 2) harsh reaction conditions, requiring no water operation; 3) high toxicity of the intermediate, such as compound 8 has cytotoxicity; 4) low total yield , less than 1%; 5) high product cost, the cost per kilogram of product reached about 150,000 yuan. Therefore, there is an urgent need for a process for producing an optical isomer of a compound of the formula A at low cost, in a simple, high yield, and high purity, thereby realizing industrial production of an optical isomer of the formula A compound. Summary of the invention
鉴于上述现有技术的问题, 本发明的目的在于提供能够廉价、 简 便且高收率、 高纯度地制备式 A化合物光学异构体的中间体, 即式 B 化合物的光学异构体。  In view of the above problems of the prior art, it is an object of the present invention to provide an intermediate which can produce an optical isomer of the compound of the formula A, which is an optical isomer of the compound of the formula B, which is inexpensive, simple, and high in yield and high purity.
本发明的另一目的在于提供上述中间体的制备方法。  Another object of the present invention is to provide a process for the preparation of the above intermediates.
本发明的再一目的在于提供使用上述中间体, 廉价、 简便且高收 率、 高纯度地制备式 A化合物的光学异构体的方法。  A further object of the present invention is to provide a process for producing an optical isomer of a compound of the formula A inexpensively, simply, and with high yield and high purity using the above intermediate.
为了实现上述目的, 本申请的发明人进行了悉心研究, 结果发现 在以式 B化合物的光学异构体混合物或外消旋体为原料时, 采用手性 樟脑磺酸作为拆分试剂, 能够得到高光学純度的式 B化合物的光学异 构体, 从而完成了本发明。 In order to achieve the above object, the inventors of the present application conducted intensive studies and found that chirality is employed when using an optical isomer mixture or a racemate of a compound of formula B as a raw material. The camphorsulfonic acid is used as a resolving agent to obtain an optical isomer of a compound of the formula B having high optical purity, thereby completing the present invention.
也就是说, 本发明提供上述结构式 B所示化合物的光学异构体的 制备方法, 其特征在于, 采用手性樟脑磺酸作为拆分试剂, 对上迷结 构式 B所示化合物的光学异构体混合物或外消旋体进行化学拆分。 具 体而言, 所述制备方法包括下述步驟 (1 )和步骤 (2 ) :  That is, the present invention provides a process for producing an optical isomer of the compound of the above formula B, characterized in that the optical isomer of the compound of the formula B is used by using chiral camphorsulfonic acid as a resolving agent. The mixture or racemate is chemically resolved. Specifically, the preparation method comprises the following steps (1) and (2):
( 1 )使结构式 B 所示化合物的光学异构体混合物或外消旋体与 D-或 L-樟脑磺酸在溶剂中进行反应, 分别生成 S-式 B化合物 -D-樟脑 磺酸盐或 R-式 B化合物 樟脑磺酸盐, 并使所得樟脑磺酸盐沉淀; ( 2 )对上述步驟 ( 1 ) 中得到的樟脑磺酸盐进行碱化处理, 由此 可以得到下式所示的 S或 R构型的式 B化合物。  (1) reacting an optical isomer mixture or a racemate of the compound of the formula B with D- or L-camphorsulfonic acid in a solvent to form an S-form B compound-D-camphorsulfonate or R-form B compound camphorsulfonate, and precipitating the obtained camphor sulfonate; (2) alkalizing the camphorsulfonate obtained in the above step (1), thereby obtaining S represented by the following formula A compound of formula B in the R or R configuration.
Figure imgf000006_0001
Figure imgf000006_0001
S-式 B化合物 R-式 B化合物 另外, 本发明还提供上述结构式 A所示化合物的光学异构体的制 备方法, 其中包括使用通过上述制备方法得到的 S或 R构型的式 B化 合物作为原料, 进行如下述反应流程 3所示的反应。 S-Form B Compound R-Form B Compound Further, the present invention also provides a process for producing an optical isomer of the compound represented by the above Structural Formula A, which comprises using the compound of the formula B in the S or R configuration obtained by the above production method as The raw material was subjected to a reaction as shown in the following Reaction Scheme 3.
Figure imgf000006_0002
Figure imgf000006_0002
R或 S构型的式 B化合物 Compound of formula B in R or S configuration
Figure imgf000007_0001
式 A化合物的光学异构体
Figure imgf000007_0001
Optical isomers of compounds of formula A
反应流程 3  Reaction process 3
采用本发明的式 B化合物光学异构体的制备方法, 能够简便、 高 纯度地获得式 B化合物的光学异构体, 使用该光学异构体, 能够廉价、 简便且高收率、 高纯度地制备具有抗抑郁效果的式 A化合物的光学异 构体。 具体实施方式  According to the method for producing an optical isomer of the compound of the formula B of the present invention, the optical isomer of the compound of the formula B can be obtained simply and with high purity, and the optical isomer can be used in an inexpensive, simple, high-yield, high-purity manner. An optical isomer of a compound of formula A having an antidepressant effect is prepared. detailed description
下面, 对本发明进行详细说明。 中间体式 B化合物光学异构体的制备  Hereinafter, the present invention will be described in detail. Preparation of intermediates B compound optical isomers
在本发明的式 B化合物的光学异构体的制备方法中, 采用手性樟 脑磺酸作为拆分试剂, 对式 B化合物的光学异构体混合物或外消旋体 进行化学拆分。 具体而言, 如下述反应流程 4 所示, 所述制备方法包 括下述步骤 ( 1 ) 和步骤 ( 2 ) :  In the preparation method of the optical isomer of the compound of the formula B of the present invention, the optical isomer mixture or the racemic compound of the compound of the formula B is chemically resolved by using chiral camphorsulfonic acid as a resolving agent. Specifically, as shown in the following Reaction Scheme 4, the preparation method comprises the following steps (1) and (2):
( 1 )使式 B化合物的光学异构体混合物或外消旋体与 D-或 L-樟 脑磺酸在溶剂中进行反应, 分别生成 S-式 B 化合物 樟脑磺酸盐或 R-式 B化合物 樟脑磺酸盐, 并使所得樟脑磺酸盐沉淀;  (1) reacting an optical isomer mixture or a racemate of the compound of the formula B with D- or L-camphorsulfonic acid in a solvent to form a S-form B compound camphorsulfonate or an R-form B compound, respectively. Camphor sulfonate, and precipitated camphor sulfonate;
( 2 )对上迷步骤 (1 ) 中得到的樟脑磺酸盐进行碱化处理, 由此 得到相对应的 S或 R构型的式 B化合物。 (2) The camphor sulfonate obtained in the above step (1) is subjected to alkalization to obtain a corresponding compound of the formula B in the S or R configuration.
Figure imgf000008_0001
Figure imgf000008_0002
Figure imgf000008_0001
Figure imgf000008_0002
R-式 B化合物 -L-樟脑磺酸盐 R-form B compound -L-camphorsulfonate
Figure imgf000008_0003
Figure imgf000008_0003
S-式 B化合物 R-式 B化合物 反应流程 4  S-form B compound R-form B compound Reaction scheme 4
( 1 ) 步骤( 1 ) (1) Step (1)
在该步驟中,使式 B化合物的光学异构体混合物或外消旋体与 D- 或 L-樟脑磺酸在溶剂中进行反应, 生成下迷结构式所示的非对映体盐 S-式 B化合物 -D-樟脑磺酸盐或 R-式 B化合物 樟脑横酸盐。 In this step, an optical isomer mixture or a racemate of the compound of the formula B is reacted with D- or L-camphorsulfonic acid in a solvent to form a diastereomeric salt S-form represented by the lower structural formula. B compound-D-camphorsulfonate or R-form B compound camphoronate.
Figure imgf000009_0001
Figure imgf000009_0001
Figure imgf000009_0002
Figure imgf000009_0002
R-式 B化合物 -L-樟脑磺酸盐 作为上述反应中使用的原料式 B化合物,可以参照 CN101712658A 所迷方法进行制备。  R-Form B Compound -L-camphorsulfonate The compound of the formula B used in the above reaction can be produced by the method of CN101712658A.
在该反应中,可以以任何比例使用所述 D-或 L-樟脑横酸与式 B化 合物的光学异构体混合物或外消旋体。 从成本的角度考虑, D-或 L-樟 脑磺酸与式 B化合物的光学异构体混合物或外消旋体的摩尔比优选为 10:1 ~ 0.5:1 , 更优选为 5: 1〜1 :1 , 最优选为 2: 1。  In this reaction, an optical isomer mixture or a racemate of the D- or L-camphoric acid and the compound of the formula B may be used in any ratio. The molar ratio of the optical isomer mixture or racemate of the D- or L-camphorsulfonic acid to the compound of the formula B is preferably from 10:1 to 0.5:1, more preferably from 5:1 to 1 from the viewpoint of cost. :1 , most preferably 2: 1.
作为在该反应中使用的溶剂, 首先, 要对式 B化合物具有一定溶 解度, 优选在室温或加热状态下式 B化合物能够完全溶解。 其次, 正 如本领域技术人员所熟知的, 该溶剂对式 B化合物光学异构体与 D-樟 脑磺酸或 L-樟脑磺酸生成的非对映异构体盐的溶解度应有一定差异。 作为上述溶剂, 并没有特别限定, 例如可以列举选自水、 醇、 酯、 酮、 氯代烃、 醚、 腈、 酰胺和亚砜等中的一种或两种以上。 其中, 优选选 自水、 甲醇、 乙醇、 '异丙醇、 乙酸乙酯、 丙酮、 二氯甲烷、 氯仿、 乙 醚、 甲基叔丁基醚、 四氢呋喃 (THF ) 、 乙腈、 二曱基甲酰胺(DMF ) 和二甲基亚砜(DMSO )中的一种或两种以上, 从收率和产品纯度的角 度考虑, 更优选选自甲醇、 乙醇、 异丙醇、 含水醇溶液、 乙酸乙酯和 丙酮中的一种或两种以上, 进一步优选为甲醇、 乙醇、 1 : 1的甲醇 -异丙 醇, 含水醇溶液。 As the solvent to be used in the reaction, first, the compound of the formula B has a certain solubility, and it is preferred that the compound of the formula B can be completely dissolved at room temperature or in a heated state. Secondly, as is well known to those skilled in the art, the solubility of the optical isomer of the compound of formula B with the diastereomeric salt formed by D-camphorsulfonic acid or L-camphorsulfonic acid should be somewhat different. The solvent is not particularly limited, and examples thereof include one or more selected from the group consisting of water, an alcohol, an ester, a ketone, a chlorinated hydrocarbon, an ether, a nitrile, an amide, and a sulfoxide. Among them, it is preferably selected from the group consisting of water, methanol, ethanol, 'isopropyl alcohol, ethyl acetate, acetone, dichloromethane, chloroform, diethyl ether, methyl tert-butyl ether, tetrahydrofuran (THF), acetonitrile, dimercaptocarboxamide ( One or more of DMF) and dimethyl sulfoxide (DMSO) are more preferably selected from the group consisting of methanol, ethanol, isopropanol, aqueous alcohol solution, ethyl acetate, and the like in terms of yield and product purity. One or more of acetone, further preferably methanol, ethanol, 1:1 methanol-isopropyl Alcohol, aqueous alcohol solution.
作为上迷反应的反应温度,并没有特别限定,例如可以为 o°c至溶 剂的回流温度。  The reaction temperature as the above reaction is not particularly limited and may be, for example, o ° c to the reflux temperature of the solvent.
作为上述反应的反应时间,并没有特别限定,例如可以为 5分钟 ~ 72小时, 优选 10分钟 ~ 24小时。  The reaction time of the above reaction is not particularly limited, and may be, for example, 5 minutes to 72 hours, preferably 10 minutes to 24 hours.
通过上述反应, 生成 S-式 B化合物 -D-樟脑磺酸盐或 R-式 B化合 物 -L-棹脑磺酸盐的沉淀, 所述沉淀的分离可以采用本领域公知的方法 进行, 例如过滤、 离心或倾析等, 其中优选的方法为过滤。  By the above reaction, a precipitate of the S-form B compound-D-camphorsulfonate or the R-form B compound-L-camphorsulfonate is formed, and the separation of the precipitate can be carried out by a method known in the art, for example, filtration. , centrifugation or decantation, etc., wherein the preferred method is filtration.
另外, 如果需要, 得到的 S-式 B化合物 -D-樟脑磧酸盐或 R-式 B 化合物 -L-樟脑磺酸盐沉淀可通过重结晶等方法进行进一步纯化。 作为 重结晶的溶剂, 并没有特别限定, 可以使用选自甲醇、 乙醇、 异丙醇、 乙酸乙酯、 丙酮、 二氯曱烷、 氯仿、 乙醚、 甲基叔丁基醚和 THF等中 的一种或两种以上, 从收率和产品純度的角度来看, 其中优选甲醇、 乙醇、 异丙醇、 乙酸乙酯和丙酮中的一种或两种以上。  Further, if necessary, the obtained S-form B compound -D-camphorate or R-form B compound -L-camphorsulfonate precipitate can be further purified by a method such as recrystallization. The solvent for recrystallization is not particularly limited, and one selected from the group consisting of methanol, ethanol, isopropanol, ethyl acetate, acetone, dichloromethane, chloroform, diethyl ether, methyl tert-butyl ether, and THF can be used. One kind or two or more kinds, and one or two or more of methanol, ethanol, isopropyl alcohol, ethyl acetate and acetone are preferable from the viewpoints of yield and product purity.
( 2 ) 步驟 (2 ) (2) Step (2)
在该步驟中, 在水不溶性有机溶剂中, 对上述步骤(1 ) 中得到的 S-式 B化合物 -D-樟脑磺酸盐或 R-式 B化合物 -L-樟脑磺酸盐进行碱化 处理, 以除去手性酸拆分试剂, 得到下式所示的、 相应的 S-式 B化合 物或 R-式 B化合物。  In this step, the S-form B compound-D-camphorsulfonate or the R-form B compound-L-camphorsulfonate obtained in the above step (1) is alkalized in a water-insoluble organic solvent. To remove the chiral acid resolving agent, a corresponding S-form B compound or R-form B compound represented by the following formula is obtained.
Figure imgf000010_0001
Figure imgf000010_0001
Figure imgf000011_0001
Figure imgf000011_0001
R-式 B化合物 在该步驟中, 所述碱可以选自金属氢氧化物、 氧化物、 碳酸盐、 碳酸氢盐及酰胺, 其中, 优选为金属氢氧化物及碳酸盐, 如氢氧化钠、 碳酸钠。其中,相对于上述樟脑磺酸盐每 1摩尔,所述碱可以使用 0.5〜10 摩尔, 优选 1〜5摩尔, 更优选 2〜4摩尔。  R-form B compound In this step, the base may be selected from the group consisting of metal hydroxides, oxides, carbonates, hydrogencarbonates and amides, of which metal hydroxides and carbonates, such as hydroxides, are preferred. Sodium, sodium carbonate. Among them, the base may be used in an amount of 0.5 to 10 moles, preferably 1 to 5 moles, more preferably 2 to 4 moles per mole of the camphorsulfonate.
作为上述反应的反应温度, 并没有特别限定, 例如可以为 0°C至溶 剂的回流温度。  The reaction temperature of the above reaction is not particularly limited and may be, for example, from 0 ° C to the reflux temperature of the solvent.
作为上述反应的反应时间,并没有特别限定,例如可以为 5分钟 ~ The reaction time of the above reaction is not particularly limited and may be, for example, 5 minutes.
72小时, 优选 10分钟 ~ 24小时。 72 hours, preferably 10 minutes to 24 hours.
另外, 正如本领域技术人员所熟知的, 用于其中一种光学异构体 的制备方法, 在将手性拆分试剂改为其对映体后, 同样可以得到另一 种光学异构体。  Further, as is well known to those skilled in the art, for the preparation of one of the optical isomers, another optical isomer can be obtained after the chiral resolving agent is changed to its enantiomer.
分离出所生成的 S-式 B化合物 樟脑磺酸盐或 R-式 B化合物 -L- 樟脑磺酸盐沉淀后, 余下的滤液或上清液经碱化处理, 可以得到富含 另一种光学异构体的混合物, 然后可用上述方法经进一步处理, 得到 另一种光学异构体。 最终产物式 A化合物光学异构体的制备  After separating the formed S-form B compound camphorsulfonate or the R-form B compound-L-camphorsulfonate precipitate, the remaining filtrate or supernatant is alkalized to obtain another optical difference. The mixture of the constructs can then be further processed by the methods described above to give another optical isomer. Preparation of optical isomers of the final product of formula A
如下述反应流程 3所示,将得到的 S-式 B化合物或 R-式 B化合物 光学异构体进行还原, 可以得到 (1 S,2R ) 、 ( 1S,2S ) 式 A化合物光 学异构体混合物或 ( 1R,2R ) 、 ( 1R,2S ) 式 A化合物光学异构体混合 物, 然后将异构体混合物进行分离, 分别可以得到式 A 化合物的 ( 1S,2R )、 ( 1S,2S )光学异构体或( 1R,2R ) 、 ( 1R,2S )光学异构体。 The optical isomer of the compound of the formula (A) can be obtained by reducing the optical isomer of the obtained S-form B compound or the R-form B compound as shown in the following Reaction Scheme 3 to obtain (1S, 2R), (1S, 2S) Mixture or (1R, 2R), (1R, 2S) a mixture of optical isomers of the compound of formula A, and then separate the mixture of isomers to obtain (1S, 2R), (1S, 2S) optics of the compound of formula A, respectively Isomer or (1R, 2R), (1R, 2S) optical isomer.
Figure imgf000012_0001
Figure imgf000012_0001
R或 S构型的式 B化合物 Compound of formula B in R or S configuration
Figure imgf000012_0002
式 A化合物的光学异构体
Figure imgf000012_0002
Optical isomers of compounds of formula A
反应流程 3  Reaction process 3
在上述反应中, 所述还原反应例如可以采用 NaBH4作为还原剂在 甲醇中进行反应, 优选为室温反应 0.5〜1小时; 也可以采用异丙醇铝作 为还原剂在异丙醇中进行反应,优选为 60~65 °C反应 24~48小时; 或者 采用本领域技术人员认为适宜的其它还原方法。 In the above reaction, the reduction reaction can be carried out, for example, by using NaBH 4 as a reducing agent in methanol, preferably at room temperature for 0.5 to 1 hour; or aluminum isopropoxide can be used as a reducing agent in isopropanol. It is preferably reacted at 60 to 65 ° C for 24 to 48 hours; or other reduction methods which are considered suitable by those skilled in the art.
所述分离例如可以采用硅胶柱分离, 其中可以使用 200: 1 的二氯 甲烷:甲醇作为洗脱剂, 或者采用本领域技术人员认为适宜的其它分离 方法。  The separation can be carried out, for example, using a silica gel column in which 200:1 of dichloromethane:methanol can be used as an eluent, or other separation methods deemed suitable by those skilled in the art can be employed.
本发明通过对式 B化合物的光学异构体混合物或外消旋体成功地 进行拆分, 为廉价、 简便且高收率、 高纯度地制备式 A化合物光学异 构体提供了一条新路线, 为其实现工业化生产开辟了新路径。 实施例  The present invention provides a new route for the preparation of optical isomers of the compound of formula A by inexpensive, simple, high yield and high purity by successfully separating the optical isomer mixture or racemate of the compound of formula B. It has opened up a new path for industrial production. Example
下面, 通过实施例进一步详细地说明本发明, 但是, 这些实施例 并不构成对本发明的任何限制。  The invention is further illustrated by the following examples, but these examples do not constitute any limitation of the invention.
光学纯度的测定方法  Method for determining optical purity
通过手性 HPLC测定光学纯度, 测定条件如下所述。 柱: CHIRALPAK#4¾合柱; The optical purity was measured by chiral HPLC, and the measurement conditions were as follows. Column: CHIRALPAK #43⁄4 combined column;
流速: lmL/min;  Flow rate: lmL/min;
测定波长: 236謹;  Measuring wavelength: 236
洗脱液: 正己烷:异丙醇:二乙胺 =75 : 25 : 0.1 , 样品溶解在洗 脱液中。  Eluent: n-hexane: isopropanol: diethylamine = 75: 25: 0.1, the sample was dissolved in the eluent.
式 A化合物的光学异构体的保留时间  Retention time of optical isomers of compounds of formula A
利用 CN101712658A中记载的方法合成式 A化合物的四种光学异 构体, 在上述手性 HPLC条件下测定各自的保留时间 (tR ) , 结果如表 1所示。 式 A化合物的四个光学异构体的保留时间 (tR )
Figure imgf000013_0001
实施例 1 S-式 B化合物- D-樟脑磺酸盐的制备
The four optical isomers of the compound of the formula A were synthesized by the method described in CN1017126 5 8A, and the respective retention times (t R ) were measured under the above chiral HPLC conditions. The results are shown in Table 1. Retention time (t R ) of four optical isomers of the compound of formula A
Figure imgf000013_0001
Example 1 Preparation of S-Form B Compound - D-camphorsulfonate
将 R,S-式 B化合物消旋体(参照 CN101712658A所述方法进行制 备) 10g ( 0.0215mol ) 添加到 300ml甲醇中, 加热至溶解, 加入 D-樟 脑磺酸 10g ( 0.043 lmol ) , 在 65°C反应 3h。 反应结束后, 在 20°C搅拌 The R, S-form B compound racemate (prepared by the method described in CN101712658A) 10g (0.0215mol) was added to 300ml of methanol, heated to dissolve, and added D-camphorsulfonic acid 10g (0.043 lmol) at 65° C reacted for 3 h. After the reaction, stir at 20 ° C
2h, 析出晶体, 抽滤, 得到 S-式 B化合物 -D-樟脑磺酸盐 5.6g。 用手性 液相色谱测得光学纯度为 91.1%。 After 2 h, crystals were precipitated and suction filtered to obtain 5.6 g of the compound of formula -D-camphorsulfonate. The optical purity was 91.1% as determined by chiral liquid chromatography.
将上述樟脑磺酸盐用乙醇重结晶, 得到光学纯度大于 99%的 S-式 B化合物 樟脑磺酸盐 4.6g。  The above camphor sulfonate was recrystallized from ethanol to obtain 4.6 g of the S-form B compound camphorsulfonate having an optical purity of more than 99%.
mp=204.5-205.5°C Mp=204.5-205.5°C
元素分析 Elemental analysis
实测值: C 65.05%, H 7.01%, C1 5.108%, 4.06%, O 13.92%, S 4.81 % 计算值: C28H33ClN2O2'C10H16O4S: C 65.43%, H 7.08%, CI 5.08%, N 4.02%, O 13.77%, S 4.62%。 实施例 2 R-式 B化合物 -L-樟脑磺酸盐的制备 Found: C 65.05%, H 7.01%, C1 5.108%, 4.06%, O 13.92%, S 4.81 % Calculated: C 28 H 33 ClN 2 O 2 'C 10 H 16 O 4 S: C 65.43%, H 7.08%, CI 5.08%, N 4.02%, O 13.77%, S 4.62%. Example 2 Preparation of R-Form B Compound-L-camphorsulfonate
将 R,S-式 B化合物消旋体(参照 CN101712658A所述方法进行制 备) 20g ( 0.043mol ) 添加到 500ml的无水乙醇中, 加热至溶解, 加入 L-樟脑磺酸 20g ( 0.0862mol ) , 在 68 °C反应 2.5h。 反应结束后, 在 10 °C搅拌 2h。 析出晶体, 抽滤, 得到 R-式 B化合物 -L-樟脑磺酸盐 12g。 用手性液相色谱测得光学纯度为 91.0%。 The R, S-form B compound racemate (prepared by the method described in CN101712658A) 20g (0.043mol) was added to 500ml of absolute ethanol, heated to dissolve, and added L-camphorsulfonic acid 20g (0.0862mol), The reaction was carried out at 68 ° C for 2.5 h. After the reaction, at 10 Stir at °C for 2 h. The crystal was precipitated and suction filtered to obtain 12 g of the compound of formula R---camphorsulfonate. The optical purity was 91.0% as determined by chiral liquid chromatography.
将上述樟脑磺酸盐用丙酮重结晶, 得到光学純度大于 99%的 R-式 B化合物 -L-樟脑磺酸盐 9g。  The above camphorsulfonate was recrystallized from acetone to obtain 9 g of an R-form B compound -L-camphorsulfonate having an optical purity of more than 99%.
mp=200.2-201.2°C Mp=200.2-201.2°C
元素分析 Elemental analysis
实测值: C 65.02%, H 7.06%, C1 5.11%, N 4.00%, O 13.98%, S 4.86% 计算值: C28H33ClN2O2'C10H16O4S: C 65.43%, H 7.08%, CI 5.08%, N 4.02%, 0 13,77%, S 4.62%。 实施例 3〜: Π 不同溶剂条件下制备 S-式 B化合物 樟脑磺酸盐 Found: C 65.02%, H 7.06%, C1 5.11%, N 4.00%, O 13.98%, S 4.86% Calculated: C 28 H 33 ClN 2 O 2 'C 10 H 16 O 4 S: C 65.43%, H 7.08%, CI 5.08%, N 4.02%, 0 13,77%, S 4.62%. Example 3~: 制备 Preparation of S-form B compound camphorsulfonate under different solvent conditions
参照实施例 1的制备方法, 在不同反应溶剂条件下制备 S-式 B化 合物 -D-樟脑磺酸盐, 再对其进行重结晶进行精制, 实验结果如下述表 2所示: 表 2 实施例 3 ~ 11实验结果  Referring to the preparation method of Example 1, the S-form B compound-D-camphorsulfonate was prepared under different reaction solvents, and recrystallized and purified. The results of the experiment are shown in Table 2 below: Table 2 Examples 3 ~ 11 experimental results
Figure imgf000014_0001
由上述实险结果可知, 在上述实施例的实^ r条件下, 均可以得到 较高纯度的非对映体盐。 实施例 12 S-式 B化合物 -D-樟脑磺酸盐和 R-式 B化合物 -L-樟脑磺酸 盐的制备
Figure imgf000014_0001
It can be seen from the above-mentioned actual risk results that under the actual conditions of the above embodiments, Higher purity diastereomeric salts. Example 12 Preparation of S-Form B Compound-D-camphorsulfonate and R-Form B Compound-L-camphorsulfonate
参照实施例 1的制备方法得到 S-式 B化合物 樟脑磺酸盐 4.6g, 用手性 HPLC测得光学纯度为 99.3%。  The S-form B compound camphorsulfonate 4.6 g was obtained by the preparation method of Example 1, and the optical purity was 99.3% as measured by chiral HPLC.
将过滤后的母液用饱和碳酸钠溶液处理, 得到富含 R异构体的式 B化合物光学异构体混合物, 再参照实施例 2的制备方法, 得到 R-式 B化合物 -L-樟脑磺酸盐 4.8g, 用手性 HPLC测得光学纯度为 99.1 %。 实施例 13 S-式 B化合物的制备  The filtered mother liquor is treated with a saturated sodium carbonate solution to obtain an optical isomer mixture of the compound of formula B rich in R isomer. Referring to the preparation method of Example 2, an R-form B compound-L-camphorsulfonic acid is obtained. The salt was 4.8 g, and the optical purity was 99.1% as determined by chiral HPLC. Example 13 Preparation of S-Formula B Compound
将 4.6g S-式 B化合物- D-樟脑横酸盐加入到 100ml二氯甲烷和 100ml水中, 搅拌, 用饱和碳酸钠溶液调节 pH=9-10, 分离有机相, 蒸 发除去有机相中的有机溶剂, 得到 S-式 B化合物 3g, 通过手性 HPLC 测定光学纯度为 99.1%。  4.6 g of the compound of the formula S-D-camphoric acid salt was added to 100 ml of dichloromethane and 100 ml of water, stirred, and the pH was adjusted to 9-10 with a saturated sodium carbonate solution, the organic phase was separated, and the organic phase was removed by evaporation. The solvent was used to obtain 3 g of an S-form B compound, and the optical purity was determined by chiral HPLC to be 99.1%.
mp=80.6-81,4°C Mp=80.6-81, 4°C
[a] i)=32.84(c-l , CHC13) 实施例 14 R-式 B化合物的制备 [a] i) = 32.84 (cl , CHC1 3 ) Example 14 Preparation of R-Form B Compound
将 9g R-式 B 化合物- L-樟脑磺酸盐加入到 200ml 二氯甲烷和 9 g of R-form B compound-L-camphorsulfonate was added to 200 ml of dichloromethane and
200ml水中, 搅拌, 用 2N氢氧化钠溶液调节 pH=9-10, 分离有机相, 蒸发除去有机相中的有机溶剂, 得到 R-式 B 化合物 5.8g, 通过手性In 200 ml of water, stir, adjust the pH to 9-10 with 2N sodium hydroxide solution, separate the organic phase, and remove the organic solvent in the organic phase to obtain R-form B compound 5.8 g, by chirality.
HPLC测定光学纯度为 99.2%。 The optical purity by HPLC was 99.2%.
mp=82.2-82.8°C Mp=82.2-82.8°C
[a]¾)=-32.68(c=l , CHC13) 实施例 15 由 S-式 B化合物制备 ( 1S,2R )和( 1S,2S )式 A化合物光 学异构体 [a] 3⁄4 ) = -32.68 (c = l , CHC1 3 ) Example 15 Preparation of (1S, 2R) and (1S, 2S) Compound A Optical Isomers from S-Formula B Compounds
将 S-式 B化合物异构体 4.65g(0.01mol)溶解于异丙醇 70ml, 加入 异丙醇铝 7.14g(0.035mol), 加入无水 A1C130.46 g ( 0.0035mol ) , 70 °C 下加热反应 6h。 蒸发除去溶剂, 加入氯仿( 100mlx3 )、 水( 100ml ) , 进行萃取, 合并氯仿层, 用硫酸镁干燥, 蒸发除去氯仿, 得到(1S,2R ) 和 (1S,2S ) 式 A化合物混合物。 4.65 g (0.01 mol) of the S-form B compound isomer was dissolved in 70 ml of isopropanol, 7.14 g (0.035 mol) of aluminum isopropoxide was added, and anhydrous A1C1 3 0.46 g (0.0035 mol) was added at 70 ° C. The reaction was heated for 6 h. The solvent was evaporated, and chloroform (100 ml×3), water (100 ml) was added, and the mixture was extracted, and the chloroform layer was combined, dried over magnesium sulfate and evaporated to remove chloroform to give (1S, 2R). And a mixture of (1S, 2S) compounds of formula A.
对上述混合物进行硅胶柱分离(洗脱剂: 二氯甲烷:甲醇 = 200:1 ) , 先出柱的为 (1S,2S )异构体, tR=30.24min, 重量为 2 g, 收率 43 % , 用手性 HPLC测得光学纯度为 99.5%。 The above mixture was subjected to silica gel column separation (eluent: dichloromethane:methanol = 200:1), and the first (1S, 2S) isomer of the column, t R = 30.24 min, weight 2 g, yield The optical purity was determined by chiral HPLC to be 43%.
后出柱的为 ( 1S,2R ) 异构体, tR=5.998min, 重量为 1.8g, 收率The post-column is (1S, 2R) isomer, t R = 5.998min, weight is 1.8g, yield
39 % , 用手性 HPLC测得光学純度为 99.4%。 实施例 16 由 R-式 B化合物制备( 1R,2S )和 ( 1R,2R ) 式 A化合物 光学异构体 The optical purity was 39.9% by chiral HPLC. Example 16 Preparation of (1R, 2S) and (1R, 2R) Formula A Compounds from R-Formula B Optical Isomers
使用与实施例 15相同的方法及原料投料量, 得到 (1R,2S )异构 体 1.9 g,收率 41%, tR=7.08min,用手性液相色谱测得光学纯度为 99.2%; 得到 R,2R )异构体 1.7g, 收率 36%, tR-14.15min, 用手性液相色普 测得光学纯度为 99.6%。 Using the same method and material feeding amount of 15 cases, to obtain (1R, 2S) isomer 1.9 g, yield 41%, t R = 7.08min, chiral liquid chromatography measured by an optical purity of 99.2%; The R, 2R) isomer was obtained in an amount of 1.7 g, yield 36%, t R - 14.15 min, and the optical purity was 99.6% as determined by chiral liquid chromatography.
由上述内容可知, 采用本发明的式 B化合物光学异构体的制备方 法, 能够简便、 高純度地获得式 B化合物的光学异构体, 使用该光学 异构体, 能够廉价、 简便且高收率、 高纯度地制备具有抗抑郁效果的 式 A化合物的光学异构体。 在本申请的说明书中, 援引中国专利申请 CN101712658A的全部 内容作为参考。 另外, 本领域普通技术人员应当理解, 对本发明技术 方案所作的任何不背离本发明精神和范围的变更、 修改和替换, 均在 本发明的范围之内。  From the above, it is understood that the optical isomer of the compound of the formula B of the present invention can be used to obtain an optical isomer of the compound of the formula B in a simple and high-purity manner, and the optical isomer can be used at a low cost, in a simple manner, and in a high yield. The optical isomer of the compound of the formula A having an antidepressant effect is prepared in a high-purity manner. In the specification of the present application, the entire contents of the Chinese patent application CN101712658A are incorporated by reference. In addition, it is to be understood by those skilled in the art that any changes, modifications, and alterations of the present invention may be made without departing from the spirit and scope of the invention.

Claims

权 利 要 求 Rights request
1、 下述结构式 B所示化合物的光学异构体的制备方法, 其特征在 于, 采用手性樟脑磺酸作为拆分试剂, 对结构式 B所示化合物的光学 异构体混合物或外消旋体进行化学拆分。 A method for producing an optical isomer of a compound represented by the following structural formula B, which comprises using a chiral camphorsulfonic acid as a resolving agent for an optical isomer mixture or a racemate of a compound of the formula B. Perform chemical resolution.
Figure imgf000017_0001
Figure imgf000017_0001
( B ) (B)
2、如权利要求 1所述的制备方法,其特征在于, 包括下述步骤( 1 ) 和步骤 (2 ) : The preparation method according to claim 1, comprising the following steps (1) and (2):
( 1 )使结构式 B 所示化合物的光学异构体混合物或外消旋体与 D-或 L-樟脑磺酸在溶剂中进行反应, 分别生成 S-式 B化合物 -D-樟脑 磺酸盐或 R-式 B化合物 -L-樟脑磺酸盐, 并使所得樟脑磺酸盐沉淀; (1) reacting an optical isomer mixture or a racemate of the compound of the formula B with D- or L-camphorsulfonic acid in a solvent to form an S-form B compound-D-camphorsulfonate or R-form B compound-L-camphorsulfonate, and precipitated the obtained camphor sulfonate;
( 2 )对上述步骤 (1 ) 中得到的樟脑磺酸盐进行碱化处理, 由此 得到相对应的 S或 R构型的式 B化合物。 (2) The camphorsulfonate obtained in the above step (1) is subjected to alkalization to obtain a corresponding compound of the formula B in the S or R configuration.
3、 如权利要求 2所述的制备方法, 其特征在于, 所述溶剂是选自 水、 醇、 酯、 酮、 氯代烃、 醚、 腈、 酰胺和亚砜中的一种或者两种以 上。  The method according to claim 2, wherein the solvent is one or more selected from the group consisting of water, an alcohol, an ester, a ketone, a chlorinated hydrocarbon, an ether, a nitrile, an amide, and a sulfoxide. .
4、 如权利要求 3所述的制备方法, 其特征在于, 所述溶剂是选自 水、 甲醇、 乙醇、 异丙醇、 乙酸乙酯、 丙酮、 二氯甲烷、 氯仿、 乙醚、 甲基叔丁基醚、 四氢呋喃、 乙腈、 二甲基甲酰胺和二甲基亚砜中的一 种或者两种以上。  The preparation method according to claim 3, wherein the solvent is selected from the group consisting of water, methanol, ethanol, isopropanol, ethyl acetate, acetone, dichloromethane, chloroform, diethyl ether, and methyl tert-butyl. One or more of a group ether, tetrahydrofuran, acetonitrile, dimethylformamide, and dimethyl sulfoxide.
5、 如权利要求 2~4中任意一项所述的制备方法, 其特征在于, 在 步骤(1 ) 中, 还包括对得到的樟脑磺酸盐沉淀进行重结晶的步骤。  The preparation method according to any one of claims 2 to 4, further comprising the step of recrystallizing the obtained camphor sulfonate precipitate in the step (1).
6、 如权利要求 5所述的制备方法, 其特征在于, 作为用于重结晶 的溶剂, 是选自甲醇、 乙醇、 异丙醇、 乙酸乙酯、 丙酮、 二氯甲烷、 氯仿、 乙醚、 甲基叔丁基醚和四氢呋喃中的一种或两种以上。 The method according to claim 5, wherein the solvent for recrystallization is selected from the group consisting of methanol, ethanol, isopropanol, ethyl acetate, acetone, and dichloromethane. One or more of chloroform, diethyl ether, methyl tert-butyl ether and tetrahydrofuran.
7、下述结构式表示的 R-式 B化合物 樟脑磺酸盐或 S-式 B化合 物 -D-樟脑磺酸盐。  7. R-form B compound represented by the following structural formula: camphorsulfonate or S-form B compound - D-camphorsulfonate.
Figure imgf000018_0001
Figure imgf000018_0001
R-式 B化合物 樟脑横酸盐  R-form B compound camphorate
Figure imgf000018_0002
Figure imgf000018_0002
S-式 B化合物 樟脑横酸盐 S-form B compound camphorate
8、 下述结构式表示的 R或 S构型的式 B化合物。 8. A compound of the formula B in the R or S configuration represented by the following structural formula.
Figure imgf000018_0003
Figure imgf000018_0003
S-式 B化合物 R-式 B化合物  S-form B compound R-form B compound
9、 权利要求 8所述的 R或 S构型的式 B化合物在制备下迷结构 式 A所示化合物的光学异构体中的用途。 9. Use of a compound of formula B of the R or S configuration of claim 8 for the preparation of optical isomers of the compound of formula A below.
Figure imgf000019_0001
Figure imgf000019_0001
(A)  (A)
10、 下述结构式 A 所示化合物的光学异构体的制备方法, 其特征在于, 包括使用权利要求 8所述的 R或 S构型的式 B化 合物作为原料, 进行下述化学式表示的反应。  A method for producing an optical isomer of a compound represented by the following structural formula A, which comprises using the compound of the formula B of the R or S configuration according to claim 8 as a raw material, and performing a reaction represented by the following chemical formula.
(1)还原 (1) Restore
(2)分离
Figure imgf000019_0002
(2) Separation
Figure imgf000019_0002
R或 S构型的式 B化合物 Compound of formula B in R or S configuration
Figure imgf000019_0003
式 A化合物的光学异构体
Figure imgf000019_0003
Optical isomers of compounds of formula A
PCT/CN2010/001766 2009-11-03 2010-11-03 Optical isomers of aralkyl piperazine derivative, preparation methods and uses thereof WO2011054185A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009100758460A CN102050801B (en) 2009-11-03 2009-11-03 Method for preparing arylpiperazines derivative optical isomer
CN200910075846.0 2009-11-03

Publications (1)

Publication Number Publication Date
WO2011054185A1 true WO2011054185A1 (en) 2011-05-12

Family

ID=43955651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/001766 WO2011054185A1 (en) 2009-11-03 2010-11-03 Optical isomers of aralkyl piperazine derivative, preparation methods and uses thereof

Country Status (2)

Country Link
CN (1) CN102050801B (en)
WO (1) WO2011054185A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101712658A (en) * 2008-10-07 2010-05-26 石药集团中奇制药技术(石家庄)有限公司 1-butyl-2-hydroxy aralkyl piperazine derivative and application as antidepressant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1181065C (en) * 2002-05-08 2004-12-22 上海医药工业研究院 Aralkylformylalkyl piperazine derivative and its application as brain nerve protector
CN1172919C (en) * 2002-06-03 2004-10-27 上海医药工业研究院 Alkyl alcohol piperazine derivative and its application in preparing medicine for treating depression
CN100415728C (en) * 2005-10-10 2008-09-03 上海医药工业研究院 Alkylol piperazine derivative optical isomer or its salt and its application

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101712658A (en) * 2008-10-07 2010-05-26 石药集团中奇制药技术(石家庄)有限公司 1-butyl-2-hydroxy aralkyl piperazine derivative and application as antidepressant

Also Published As

Publication number Publication date
CN102050801B (en) 2013-05-29
CN102050801A (en) 2011-05-11

Similar Documents

Publication Publication Date Title
JP5503546B2 (en) Separation of 4,5-dimethoxy-1- (methylaminomethyl) -benzocyclobutane
US8367847B2 (en) Production of monatin enantiomers
EP2344468A1 (en) Process for the preparation of ramelteon
JP2019501923A (en) Chiral resolution method of N- [4- (1-aminoethyl) -phenyl] -sulfonamide derivative using polar aprotic solvent
EP3653607B1 (en) Process for the preparation of enantiomerically enriched 3-aminopiperidine
JP4268055B2 (en) Purified lasofoxifene and a method for purifying racemic rasofoxifene by recrystallization
WO2011054185A1 (en) Optical isomers of aralkyl piperazine derivative, preparation methods and uses thereof
JP2009518380A (en) Preparation of 2-chloroethoxy-acetic acid-N, N-dimethylamide
WO2011054183A1 (en) Preparation method of optical isomers of 1-butyl-2-hydroxy-aralkyl alcohol piperazine derivative
MX2013000463A (en) Process for the preparation of contrast agents.
WO2002020461A1 (en) 3-amino-1-indanole, method of synthesizing the same and method of optical resolution
HUT56050A (en) Process for resolving 2-amino-4phenyl-butane
EP2739610B1 (en) Process for the manufacture of ivabradine and of intermediates of synthesis thereof
JP7426832B2 (en) Iguratimod with a novel crystal structure and its production method
JP2007513936A (en) Method for the division of nefopam
JP4126921B2 (en) Process for producing optically active β-phenylalanine derivative
JP2016222628A (en) Method for producing duloxetine hydrochloride
JP4402500B2 (en) Purification method of iopamidol
JP4109446B2 (en) Process for producing pure trans-2-[(α-methylbenzyl) amino] cyclopentanol as a diastereoisomer
CN110885315A (en) Preparation method of important intermediate of levosimendan
JP5456871B2 (en) Selective process for producing (+)-cis-sertraline
JP5704182B2 (en) Process for producing optically active tetrahydrofuran-2-carboxylic acid
CA2930089A1 (en) Fingolimod hydrochloride process
EP3068746A1 (en) Process for the preparation of enatiomerically pure 1-aminoindan
JP4193437B2 (en) Optically active carboxylic acids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10827799

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10827799

Country of ref document: EP

Kind code of ref document: A1